Drug Profile
Daratumumab/hyaluronidase - Janssen Biotech
Alternative Names: DARA-PH20; DARA-SC; daratumumab and hyaluronidase-fihj; Daratumumab subcutaneous - Janssen Biotech; DARZALEX FASPRO; DARZALEX SC; DARZALEX-SC; Darzquro; Recombinant human hyaluronidase-based subcutaneous daratumumabLatest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Janssen Biotech
- Developer Janssen Research & Development; Johnson & Johnson Innovative Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Amyloid light-chain amyloidosis; Multiple myeloma
- Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 30 Jan 2024 Johnson & Johnson files sBLA for treatment of patient with Multiple myeloma in USA
- 30 Jan 2024 Efficacy data from a phase III PERSEUS trial in Multiple myeloma released by Johnson and Johnson
- 12 Jan 2024 Janssen Research & Development completes phase-III COLUMBA trial in Multiple myeloma (Second-line therapy or greater) in Australia, Brazil, Canada, Greece, Czech Republic, France, Israel, Italy, Japan, Poland, Russia, South Korea, Taiwan, Ukraine, United Kingdom, Spain, Sweden and USA (SC) (NCT03277105) (EudraCT2017-000206-38)